Abstract
Alzheimer's Disease (AD) is a progressive neurological disorder, and its association with type 2 diabetes mellitus (T2DM) has increased its intricacy to many folds. Thus, targeting both associated disorders with a single therapeutic agent appears to be promising. Anti-AD potency of a new class of anti-diabetic agents, i.e., Sodium-Glucose Co-transporters 2 (SGLT2) inhibitors have been investigated in the present study. The docking approach was applied to elucidate the interaction pattern of natural SGLT2 inhibitors (Acerogenin A, Alstiphyllanine D, epsilon-viniferin, Phlorizin, and Sophoraflavanone G) with AD targets. Here, Acerogenin A, epsilon-viniferin and Sophoraflavanone G showed better binding with almost all AD targets as compared to positive controls, except beta-secretase where positive control verubecestat showed better results than these inhibitors. Also, epsilon-viniferin and Sophoraflavanone G have shown potency against direct amyloid beta aggregation. We state that SGLT2 inhibitors based scaffolds could be explored to develop dual therapeutic agents against T2DM and AD.